Zacks Investment Research downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a research note released on Friday morning, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

Other research analysts have also issued reports about the stock. TheStreet lowered shares of Spero Therapeutics from a c- rating to a d+ rating in a report on Monday, July 29th. HC Wainwright reissued a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a report on Monday, August 12th. Cantor Fitzgerald reissued a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a report on Thursday, May 9th. Finally, ValuEngine raised shares of Spero Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Spero Therapeutics presently has an average rating of Buy and a consensus target price of $20.60.

SPRO traded up $0.57 during trading hours on Friday, reaching $10.14. 11,800 shares of the stock traded hands, compared to its average volume of 34,531. The firm’s fifty day simple moving average is $10.37 and its two-hundred day simple moving average is $11.54. The company has a market cap of $177.42 million, a price-to-earnings ratio of -3.90 and a beta of 2.08. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $14.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.66 and a quick ratio of 17.48.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.10). The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $6.95 million. Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. On average, research analysts predict that Spero Therapeutics will post -2.94 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new position in shares of Spero Therapeutics in the 2nd quarter worth about $25,000. Marshall Wace LLP bought a new position in shares of Spero Therapeutics in the 1st quarter worth about $39,000. D.A. Davidson & CO. bought a new position in shares of Spero Therapeutics in the 2nd quarter worth about $115,000. Virtu Financial LLC bought a new position in shares of Spero Therapeutics in the 1st quarter worth about $134,000. Finally, Wells Fargo & Company MN lifted its position in shares of Spero Therapeutics by 187.9% in the 2nd quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after buying an additional 8,915 shares during the last quarter. 46.75% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Further Reading: Green Investing

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.